Literature DB >> 27881008

miR-33a expression sensitizes Lgr5+ HCC-CSCs to doxorubicin via ABCA1.

H Hou, Y Kang, Y Li, Y Zeng, G Ding, J Shang.   

Abstract

Cancer stem cells (CSCs) are responsible for the unrestrained cell growth and chemo-resistance of malignant tumors. Reports about miR-33a in different type of cancer are limited, and it remains elusive whether there is a link between miR-33a and chemo-resistance of CSCs. Here we report that Lgr5+ hepatocellular carcinoma (HCC) cells from primary tissues and cell lines behave similarly to CSCs and are chemo-resistant to doxorubicin. Significantly, reduced miR-33a expression is associated with the chemo-resistance of Lgr5+ HCC-CSCs, accompanied by an overexpression of ABCA1 which is identified as target of miR-33a by mainly using miRNA luciferase assay and western-blotting. We demonstrate that down-regulation of miR-33a expression directly contributes to chemo-resistance of Lgr5+ HCC-CSCs, and restoring miR-33a expression sensitizes them to doxorubicin via apoptosis by mainly using TUNEL assay, soft agar colony formation assay and xenograft assay. Additionally, reduced miR-33a expression in HCC tissues is associated with chemo-response and poor patient survival, which suggests the therapeutic potential of miR-33a. In conclusion, our work indicates that ectopic miR-33a expression sensitizes Lgr5+ HCC-CSCs to doxorubicin via direct targeting ABCA1, which sheds new light on understanding the mechanism of chemo-resistance in HCC-CSCs and contributes to development of potential therapeutics against HCC.

Entities:  

Keywords:  ABCA1; Lgr5; cancer stem cells chemo-resistance hepatocellular carcinoma.; miR-33a

Mesh:

Substances:

Year:  2017        PMID: 27881008     DOI: 10.4149/neo_2017_110

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  14 in total

Review 1.  MicroRNA regulation of liver cancer stem cells.

Authors:  Weiyang Lou; Jingxing Liu; Yanjia Gao; Guansheng Zhong; Bisha Ding; Liang Xu; Weimin Fan
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

Review 2.  The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update.

Authors:  Zahra Torki; Davood Ghavi; Solmaz Hashemi; Yazdan Rahmati; Dara Rahmanpour; Majid Pornour; Mohammad Reza Alivand
Journal:  Cancer Chemother Pharmacol       Date:  2021-09-12       Impact factor: 3.333

Review 3.  Roles of ABCA1 in cancer.

Authors:  Kun Wu; Longwei Zou; Xiaoyong Lei; Xiaoyan Yang
Journal:  Oncol Lett       Date:  2022-08-19       Impact factor: 3.111

Review 4.  Connecting Cholesterol Efflux Factors to Lung Cancer Biology and Therapeutics.

Authors:  Maria Maslyanko; Ryan D Harris; David Mu
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

5.  RNA-seq reveals distinctive RNA profiles of small extracellular vesicles from different human liver cancer cell lines.

Authors:  Martina Berardocco; Annalisa Radeghieri; Sara Busatto; Marialucia Gallorini; Chiara Raggi; Clarissa Gissi; Igea D'Agnano; Paolo Bergese; Armando Felsani; Anna C Berardi
Journal:  Oncotarget       Date:  2017-08-24

6.  A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer.

Authors:  Jian-Feng Li; Yuan-Yuan Niu; Yan-Li Xing; Feng Liu
Journal:  Biosci Rep       Date:  2019-05-31       Impact factor: 3.840

7.  Cancer Stem Cells: Emergent Nature of Tumor Emergency.

Authors:  Yaroslav R Efremov; Anastasia S Proskurina; Ekaterina A Potter; Evgenia V Dolgova; Oksana V Efremova; Oleg S Taranov; Aleksandr A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Front Genet       Date:  2018-11-16       Impact factor: 4.599

8.  The Stem Cell Phenotype of Aggressive Breast Cancer Cells.

Authors:  Naira V Margaryan; Hannah Hazard-Jenkins; Mohamad A Salkeni; Matthew B Smolkin; James A Coad; Sijin Wen; Elisabeth A Seftor; Richard E B Seftor; Mary J C Hendrix
Journal:  Cancers (Basel)       Date:  2019-03-08       Impact factor: 6.639

Review 9.  Cancer stem cells and strategies for targeted drug delivery.

Authors:  Jin Cao; Shubhmita Bhatnagar; Jiawei Wang; Xueyong Qi; Swayam Prabha; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2020-10-23       Impact factor: 5.671

10.  Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux.

Authors:  Angie M Torres-Adorno; Heidi Vitrac; Yuan Qi; Lin Tan; Kandice R Levental; Yang-Yi Fan; Peiying Yang; Robert S Chapkin; Bedrich L Eckhardt; Naoto T Ueno
Journal:  Oncogene       Date:  2018-11-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.